[A19-38] Cabozantinib (hepatocellular carcinoma) - Addendum to Commission A18-85
Last updated 06.07.2019
Project no.:
A19-38
Commission:
Commission awarded on 24.05.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Hepatocellular carcinoma after prior sorafenib therapy
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A18-85 | Cabozantinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G19-11 | Cabozantinib (hepatocellular carcinoma) - Second Addendum to Commission A18-85 | Commission completed |
Federal Joint Committee (G-BA)
2019-06-06 A G-BA decision was published.